User profiles for Michel Moutschen

Michel Moutschen

Université de Liège (ULiège) et CHU de Liège
Verified email at ulg.ac.be
Cited by 9307

[PDF][PDF] Deleterious mutations in LRBA are associated with a syndrome of immune deficiency and autoimmunity

…, K Phadwal, AK Simon, M Moutschen… - The American Journal of …, 2012 - cell.com
Most autosomal genetic causes of childhood-onset hypogammaglobulinemia are currently
not well understood. Most affected individuals are simplex cases, but both autosomal-…

Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and …

…, C Vandermeulen, M Moutschen… - Journal of Infectious …, 2007 - academic.oup.com
Background. To date, there is no commercially available vaccine to prevent infectious
mononucleosis, a disease frequently induced by Epstein-Barr virus (EBV) infection in adolescents …

[HTML][HTML] Canakinumab for the treatment of autoinflammatory recurrent fever syndromes

…, A Zeft, I Calvo Penades, M Moutschen… - … England Journal of …, 2018 - Mass Medical Soc
Background Familial Mediterranean fever, mevalonate kinase deficiency (also known as the
hyperimmunoglobulinemia D syndrome), and the tumor necrosis factor receptor–associated …

[HTML][HTML] Development of a clinical decision support system for severity risk prediction and triage of COVID-19 patients at hospital admission: an international …

…, J Guiot, AN Frix, R Louis, M Moutschen… - European …, 2020 - Eur Respiratory Soc
Background The outbreak of coronavirus disease 2019 (COVID-19) has globally strained
medical resources and caused significant mortality. Objective To develop and validate a …

Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4–insufficient subjects

…, A Plebani, C Price, KE Sullivan, M Moutschen… - Journal of Allergy and …, 2018 - Elsevier
Background Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative immune regulator.
Heterozygous CTLA4 germline mutations can cause a complex immune dysregulation …

[HTML][HTML] Convalescent plasma for Covid-19–induced ARDS in mechanically ventilated patients

…, JB Mesland, G Meyfroidt, M Moutschen… - … England Journal of …, 2023 - Mass Medical Soc
Background Passive immunization with plasma collected from convalescent patients has
been regularly used to treat coronavirus disease 2019 (Covid-19). Minimal data are available …

[HTML][HTML] An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and …

…, J Vila, A Burny, N Clumeck, M Moutschen… - PLoS …, 2015 - journals.plos.org
The persistence of latently infected cells in patients under combinatory antiretroviral therapy
(cART) is a major hurdle to HIV-1 eradication. Strategies to purge these reservoirs are …

Vaccinations in patients with immune-mediated inflammatory diseases

JF Rahier, M Moutschen, A Van Gompel… - …, 2010 - academic.oup.com
Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis,
are at increased risk of infection, partially because of the disease itself, but mostly because of …

[HTML][HTML] Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection

…, S Poutrel, J Piette, Y De Launoit, M Moutschen… - PloS one, 2009 - journals.plos.org
The persistence of transcriptionally silent but replication-competent HIV-1 reservoirs in Highly
Active Anti-Retroviral Therapy (HAART)-treated infected individuals, represents a major …

[HTML][HTML] Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue

…, A De Roover, L Kohnen, AJ Scheen, M Moutschen… - Diabetologia, 2013 - Springer
Aims/hypothesis Obesity is a heterogeneous condition comprising both individuals who
remain metabolically healthy (MHO) and those who develop metabolic disorders (metabolically …